Protocol Ledger

NCT06937944 · Phase III · RECRUITING

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

Interventional Phase III clinical trial protocol NCT06937944 sponsored by JHM BioPharma (Tonghua) Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-30 Enrollment: 669 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06937944
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)669 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06937944
Protocol FieldVerified Registry Value
NCT IdentifierNCT06937944
Consolidated Lead SponsorJHM BioPharma (Tonghua) Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment669 participants (ESTIMATED)
Registered Start Date2025-04-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI